HUMAN AMYLOID IMAGING CONFERENCE
January 15-17, 2020
The event will be held at the Kovens Conference Center at the Florida International University. Access to all sessions, meals, networking receptions will require a conference badge.
The 2020 Program will be published late November/early December 2019.
HAI’s mobile app provides all the information on the program (with ability to save sessions to your conference schedule), poster presentations, FAQs, logistics, past years’ keynote videocasts, etc.
Scan the QR code with your mobile phone or access the download through this link: https://my.yapp.us/HAICONF
|10:30 am||Check-in (Grande Promenade Foyer)|
|11:45||Welcome Notes||Keith Johnson, Massachusetts General Hospital, Boston, MA, US|
|12:00 pm||SESSION 1: Tracer properties||CHAIRS:
Roger Gunn, Invicro, Boston, MA, US/Imperial College London, London, UK
Bradley Christian, University of Wisconsin-Madison, Madison, WI, US
|12:00||Head-to-head in vivo comparison of tau positron emission tomography ligands [18F]Flortaucipir (AV1451) and RO948||Michael Schöll, University of Gothenburg, Gothenburg, Sweden|
|12:15||Retrospective comparison of [F-18]MK-6240, [F-18]THK5351 and [F-18]THK-5317 ((S)-THK-5117) in subjects scanned with all three PET tracers||Tobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US|
|12:30||Head-to-Head Comparison of neurofibrillary tangles imaging in Alzheimer's disease||Pedro Rosa-Neto, McGill University, Montreal, QC, Canada|
|12:45||Assessment of longitudinal change of tau pathology in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imaging||Sandra Sanabria Bohorquez, Genentech, Inc., South San Francisco, CA, US|
|1:00||Evaluation of 18F-PI-2620, a novel selective tau tracer for the assessment of Alzheimer's and non-Alzheimer's tauopathies||Victor Villemagne, Austin Health/The University of Melbourne, Melbourne, Australia|
|1:15||Evidence of differential in vitro and in vivo binding of APN-1607 in progressive supranuclear palsy and Alzheimer's disease||Cristian Salinas, Biogen, Cambridge, MA, US|
|1:30||Discussion Session 1|
|2:00||POSTER SESSION 1 and Coffee Break|
|3:30||SESSION 2: Methods||CHAIRS:
Robert Koeppe, University of Michigan Medical School, Ann Arbor, MI, US
Mark Lubberink, Uppsala University, Uppsala, Sweden
|3:30||Variability of uptake in potential reference regions for longitudinal flortaucipir-PET analysis||Jungho Cha, University of California, San Francisco, San Francisco, CA, US|
|3:45||Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer's disease and controls||Tessa Timmers, Amsterdam UMC, Amsterdam, The Netherlands|
|4:00||AmyloidIQ demonstrates increased power in longitudinal Amyloid PET studies||Alexander Whittington, Invicro, Boston, MA, US/Imperial College London, London, UK|
|4:15||Evaluation of the Centiloid scale for use in multi-amyloid PET tracer, multi-center trials||Jacob Hesterman, Invicro, Boston, MA, US|
|4:30||A comparison of partial volume correction techniques for measuring change in Serial AV-1451 Tau PET SUVR||Christopher Schwarz, Mayo Clinic, Rochester, MN, US|
|4:45||Detecting the earlier stages of amyloid deposition||Tengfei Guo, University of California, Berkeley, CA, US|
|5:00||Discussion Session 2|
|5:30||Keynote Lecture||Richard Carson, Yale University, New Haven, CT, US|
|7:30am||Check-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)|
|8:30||SESSION 3: Neuropathological validation of amyloid and tau tracers||CHAIRS:
Laetitia Lemoine, Karolinska Institute, Stockholm, Sweden
Rik Vandenberghe, KU Leuven, Leuven, Belgium
|8:30||Neuropathologic correlates of [11C]PiB PET and [11C]altropane dopamine transporter PET in the Lewy body diseases||Stephen Gomperts, Massachusetts General Hospital, Boston, MA, US|
|8:45||Postmortem analyses of PiB and Flutemetamol integrated density measures in diffuse and neuritic plaques in Alzheimer's disease||Milos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, US|
|9:00||In vitro characterisation of 3H-MK6240 in human autopsy brain tissue in comparison to the first generation tau PET tracers||Mona-Lisa Malarte, Karolinska Institute, Stockholm, Sweden|
|9:15||Postmortem binding study of 18F-AV1451 in semantic variant primary progressive aphasia||Rik Vandenberghe, University Hospitals Leuven/KU Leuven, Leuven, Belgium
|9:30||Neuropathologic maturity of neurofibrillary tangles: implications for tau PET imaging||Melissa Murray, Mayo Clinic Jacksonville, Jacksonville, FL, US|
|9:45||Discussion Session 3|
|10:15||POSTER SESSION 2A and Coffee Break|
|11:00||SESSION 4: In vivo-postmortem correlates of flortaucipir PET||CHAIRS:
Teresa Gomez-Isla, Massachusetts General Hospital, Boston, MA, US
David Wolk, University of Pennsylvania, Philadelphia, PA, US
|11:00||Pathologic correlations of in vivo [18F]-AV-1451 imaging in autopsy-confirmed Alzheimer's disease, Frontotemporal lobar degeneration with TDP-43 inclusions and control cases||Cinthya Aguero, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, US|
|11:15||[18F]Flortaucipir PET and pathology correlations in Alzheimer's disease, non-Alzheimer's tauopathies, and other neurodegenerative diseases||David Soleimani-Meigooni, University of California, San Francisco, San Francisco, CA, US|
|11:30||Tau PET imaging correlates with neuropathology||Val Lowe, Mayo Clinic, Rochester, MN, US|
|11:45||Relationships between Flortaucipir PET signal and tau neurofibrillary tangle pathology at autopsy||Mark Mintun, Avid Radiopharmaceuticals, Philadelphia, PA, US|
|12:00||Discussion Session 4|
(This lecture will be recorded)
|Michel Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK|
|2:45||SESSION 5: Modeling amyloid & tau relationships and spread||CHAIRS:
Elizabeth Mormino, Stanford University, Palo Alto, CA, US
Michel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany
|2:45||Data-driven characterization of cross-sectional and longitudinal molecular imaging in aging and Alzheimer's disease||Hugo Botha, Mayo Clinic, Rochester, MN, US|
|3:00||The cortical site of origin and initial spread of medial temporal tauopathy assessed with positron emission tomography||Justin Sanchez, Massachusetts General Hospital, Boston, MA, US|
|3:15||Amyloid and tau pathology are related to functional signal homogeneity and isolation of the hippocampus in cognitively healthy older adults||Theresa Harrison, University of California Berkeley, Berkeley, CA, US|
|3:30||Cross-method identification of earliest regions to display amyloid burden||Isadora Lopes Alves, VU University Medical Center, Amsterdam, The Netherlands|
|3:45||Tau organization precedes Aβ deposition across the brain cortex||Tharick Pascoal, McGill University, Montreal, QC, Canada|
|4:00||Increased task activation and amyloid independently explain advanced tau pathology in older adults||Anne Maass, German Center for Neurodegenerative Diseases, Magdeburg, Germany|
|4:15||Discussion Session 5|
|4:45||POSTER SESSION 2B and Coffee Break|
|5:30 - 7:30||Networking Reception|
|7:30am||Check-in (Grande Promenade Foyer) and Breakfast (Starlight Ballrooom - 18th Floor)|
|8:30||SESSION 6: PET and fluid biomarkers||CHAIRS:
Oskar Hansson, Lund University, Lund, Sweden
Susan Landau, University of California, Berkeley, Berkeley, CA, US
|8:30||Longitudinal investigation of concordant vs. discordant amyloid CSF/PET biomarkers||Arianna Sala, Karolinska Institute, Stockholm, Sweden|
|8:45||CSF and PET tau measures in different stages of Alzheimer's disease||Niklas Mattsson, Lund University, Lund, Sweden|
|9:00||Predicting brain amyloidosis using peripheral blood-based gene expression and early stage neurodegeneration biomarkers||Apoorva Bharthur Sanjay, Indiana University School of Medicine, Indianapolis, IN, US|
|9:15||Friend or foe? Regional dependent roles of neuroinflammation in Alzheimer's disease pathophysiology||Min Su Kang, McGill Centre for Studying in Aging, Verdun, QC, Canada|
|9:30||Discussion Session 6|
|10:00||POSTER SESSION 3A and Coffee Break|
|10:45||SESSION 7: Multi-modality: cognitively normal||CHAIRS:
William Jagust, University of California, Berkeley, Berkeley, CA, US
Tobey Betthauser, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US
|10:45||Protective effect of physical activity on prospective cognitive decline and longitudinal neurodegeneration in clinically normal older adults with elevated β-amyloid burden||Jennifer Rabin, Massachusetts General Hospital, Boston, MA, US|
|11:00||MRI measures of neurodegeneration and vascular injury, but not smyloid status predict cognitive decline in normal individuals followed for more than 9 Years||Charles DeCarli, University of California at Davis, Sacramento, CA, US|
|11:15||Fluorodeoxyglucose and Flortaucipir PET independently predict subsequent cognitive decline in clinically normal adults with elevated amyloid||Bernard Hanseeuw, Massachusetts General Hospital, Boston, MA, US|
|11:30||MK-6240 and PIB PET are associated with retrospective cognitive trajectories in late-middle aged persons clinically unimpaired at baseline||Sterling Johnson, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US|
|11:45||Individual variations in sleep architecture are associated with tau PET, cognition, and functional network architecture: preliminary findings from the Harvard Aging Brain Study||Jasmeer Chhatwal, Massachusetts General Hospital, Boston, MA, US|
|12:00||Discussion Session 7|
Tau strains and spreading in pure tauopathies and Alzheimer’s disease
(This lecture will be recorded)
|John Trojanowski, University of Pennsylvania, Philadelphia, PA, US
|2:30||SESSION 8: Multi-modality: patient populations||CHAIRS:
Ann Cohen, University of Pittsburgh, Pittsburgh, PA, US
Keith Johnson, Massachusetts General Hospital, Boston, MA, US
|2:30||Tau imaging with [18F]Flortaucipir predicts the severity and the topography of subsequent cortical atrophy in patients with Alzheimer's disease||Renaud La Joie, University of California, San Francisco, San Francisco, CA, USA|
|2:45||Epidemic spreading of tau through human functional brain connections||Jacob Vogel, Montreal Neurological Institute, McGill University, Montreal, QC, Canada|
|3:00||Spatial extent and topographical relationships between pathology accumulation and neurodegeneration in Alzheimer's disease||Leonardo Iaccarino, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA, US|
|3:15||Functional connectivity associated with tau levels in aging, Alzheimer's, and small-vessel disease||Nicolai Franzmeier, Ludwig-Maximilians-Universität LMU, Munich, Germany|
|3:30||Associations between longitudinal Aβ and cross-sectional tau in adults with Down syndrome||Dana Tudorascu, University of Pittsburgh, Pittsburgh, PA, US|
|3:45||Discussion Session 8|
|4:15||POSTER SESSION 3B and Coffee Break|
|5:05||SESSION 9: Clinical applications||CHAIRS:
Pedro Rosa-Neto, McGill University, Montreal, QC, Canada
Gil Rabinovici, University of California, San Francisco, CA, US
|5:05||Tau PET imaging with 18F-PI2620 in aging and neurodegenerative diseases||Elizabeth Mormino, Stanford University, Palo Alto, CA, US|
|5:20||In vivo distribution pattern of 18F-PM-PBB3 (18F-APN-1607) and its relationship with clinical features in diverse 4-repeat tauopathies||Hitoshi Shimada, National Institute of Radiological Sciences/National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan|
|5:35||Tau imaging with 18F-MK6240 in Alzheimer's disease and in past traumatic brain injury||Christopher Rowe, Austin Health/The University of Melbourne, Melbourne, Australia|
|5:50||[18F]-AV-1451 binding profile in early and late-onset Alzheimer's disease and suspected non-Alzheimer pathophysiology||Eddie Stage, Indiana University School of Medicine, Indianapolis, IN, US|
|6:05||Towards a topographic imaging biomarker of TDP-43 pathology in amnestic dementia: patient stratification based on FDG-PET patterns in autopsy-confirmed cases||Michel Grothe, German Center for Neurodegenerative Diseases, Rostock, Germany|
|6:20||Discussion Session 9|
The 18th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) will follow immediately on January 18-19, 2020 at the same venue.
2020 KEYNOTE LECTURES
ALAN EVANS, PhD
Dr. Alan Evans is a James McGill Professor of Neurology and Neurosurgery, Psychiatry and Biomedical Engineering at McGill University since 2009, and a researcher in the McConnell Brain Imaging Centre (BIC) of the Montreal Neurological Institute.
He is co-director of the Ludmer Centre for Neuroinformatics and Mental Health and is Principal Investigator of CBRAIN, a pan-Canadian project to integrate Canadian brain research with the Compute Canada high-performance computing grid. He is the sole Canadian participant in the $1.1 billion European Human Brain Project, and is a co-principal investigator of the Big Brain project. He is Scientific Director of McGill’s $84 million CFREF project, “Healthy Brains for Healthy Lives.”
Dr. Evans heads the Data Coordinating Center for a large NIH multi-centre MRI study of normal pediatric development. This provides a web-accessible reference database of neuroanatomical and behavioral maturation. Dr. Evans was principal investigator in the Montreal Consortium for Brain Imaging Research (MCBIR), which was founded in 2000 with a $35 million award from the Canada Foundation for Innovation. He was a co-founder of the International Consortium for Brain Mapping (ICBM), a multinational effort funded by the U.S. Human Brain Project to create a computational atlas of the adult human brain. He was one of the founders of the Organization for Human Brain Mapping (OHBM), serving in numerous positions on the OHBM Council since 1995.
Dr. Evans’ research interests include cognitive neuroimaging, neuroanatomical variability, and image-processing methodologies for PET and MRI. He pioneered the technique of multi-modal 3D brain imaging with PET and MRI, which provides detailed 3D images of brain anatomy.
As BIC Coordinator from 1992 to 2000, Dr. Evans fostered the development of brain “activation” studies in which specific brain regions show subtle changes in blood flow in response to cognitive and sensorimotor stimuli. This so-called brain-mapping technique is widely used to map human brain functions. Dr. Evans extended these techniques to large-scale studies of brain anatomy. This work has spun off a new company, Biospective Inc., which performs fully automated analysis of neuroimaging databases collected as part of pharmaceutical clinical trials.
Dr. Evans has published over 550 peer-reviewed papers, and is a member of numerous international advisory boards, review panels and research collaborations. He was acknowledged as a Thompson-Reuters Highly Cited Scientist for 2014 and 2015 (top 1% in Neuroscience and Behaviour).
JULIE SCHNEIDER, MD, MS
Dr. Julie A. Schneider is the The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology (Neuropathology) and Neurological Sciences, and Associate Director at the Rush Alzheimer’s Disease Center, at Rush University Medical Center. She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University in Atlanta and is board certified in both specialties.
Dr. Schneider is also certified in Geriatric Neurology, and has a Master’s Degree in Clinical Research with a focus in Epidemiology. She is the Neuropathology Core Leader of the Rush Alzheimer’s Disease Center and the senior neuropathologist for multiple studies including the Religious Orders Study, Rush Memory and Aging Project, and Rush Minority Aging Research Study, Rush Latino Core, and NCRAD (National Cell Repository for Alzheimer’s disease).
Dr. Schneider has provided peer review for over 25 journals; has been invited to multiple journal editorial boards; and has provided numerous grant peer reviews for the National Institutes of Health, Alzheimer’s Association, and other agencies. She has served on numerous scientific and external national and international advisory boards for academia and industry; and has presented findings from her research both nationally and internationally.
Dr. Schneider has extensive experience with clinical-pathologic epidemiologic studies of aging and dementia and has over 300 peer-reviewed publications and 4 book chapters. She also has extensive experience collaborating with researchers, participating in multicenter grants and initiatives, and partnerships with industry to advance science.
The foundation of Dr. Schneider’s research is the exploration of pathologic factors in the clinical expression of cognitive decline in aging, with a focus on vascular, TDP-43, hippocampal sclerosis and mixed pathologies in Alzheimer’s and related dementias.
Dr. Schneider has over 300 peer-reviewed publications and an H-factor of 104. Her current research leverages neuropathology to advance understanding of risk, methods for diagnosis, and biomarker development for vascular, TDP, and mixed pathologies.
LI-HUEI TSAI, PhD
Dr. Li-Huei Tsai is a leader in understanding the molecular pathophysiology of neurological disorders affecting cognition. Her work has brought new mechanisms for learning, memory and neurodegeneration to light and suggests new paths for combating age-related memory loss.
Landmark discoveries include pinpointing major genetic risk for Alzheimer’s disease to immune genes, identifying chromatin-modifiers and kinases that regulate brain flexibility and can be targeted to improve cognition in Alzheimer’s disease, and discovering that genomic integrity is critical for neuronal protection during both aging and neurodegenerative disease.
In 2019, Dr. Tsai won the Hans Wigzell Prize in Medicine for 2018 for her innovative research in trying to understand the etiology and possible treatment of Alzheimer’s disease. She is a recipient of the Young Investigator Award, Metropolitan Life Foundation, Outstanding Contributor Award of the Alzheimer Research Forum, the NIH Cantoni Lecture Award and the Glenn Award For Research in Biological Mechanisms of Aging.
Dr. Tsai is Director of the The Picower Institute for Learning and Memory, Picower Profess or Neuroscience and Senior Associate Member, Broad Institute.
She is a Fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences, the Neurodegeneration Consortium and Taiwan’s Academia Sinica.
Dr. Tsai has authored and co-authored over 130 peer-reviewed articles published in Nature, Cell, Neuron, Molecular Psychiatry, The Journal of Neuroscience, Nature Neuroscience, and the Proceedings of the National Academy of Sciences. Her research has been featured in National Geographic and the Boston Globe.